Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 613-620

  Schouest, Jonathan M ^a   Luu, Teresa K ^a   Moy, Ronald L ^a  

^a Moy Fincher Facial Plastics/Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOEFFECT EGF SERUM; DNA DEFENSE SPF 30 +; GAMMA UROGASTRONE; SPF 30; SUNSCREEN; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BARLEY; CLINICAL EVALUATION; COLOR VISION DEFECT; CONTROLLED STUDY; FACE; FEMALE; FOLLOW UP; HUMAN; HYGIENE PRODUCT; PHOTOGRAPHY; POROSITY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RHYTIDOPLASTY; SKIN DEFECT; SKIN PIGMENTATION; STATISTICAL SIGNIFICANCE; TREND STUDY; VITAL SIGN;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; EPIDERMAL GROWTH FACTOR; FACE; FEMALE; FOLLOW-UP STUDIES; HORDEUM; HUMANS; MIDDLE AGED; QUESTIONNAIRES; SKIN AGING; SKIN PIGMENTATION;

EID: 84860909292     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol. 2008;128:1365-1374. (Pubitemid 351693180)
2. Brown Lg, Nanney BL, Griffen J et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 1989;321:76-79
3. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol. 1992;18:604-606.
4. Pastor JC and Calonge M. Epidermal growth factor and corneal wound healing. Cornea. 1992;11:311-314.
5. Tsang MW, Wonk WK, Hung CS et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856-1861. (Pubitemid 36929133)
6. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg. 2006;56:394-399.
7. Fernandez-Montequin JI, Infante-Critia E, Valenzuela-Silva C et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4:333-343. (Pubitemid 350264799)
8. Lee SW, Moon SY, Kim YH, Hong JP. The use of recombinant human epidermal growth factor to promote healing for chronic radiation ulcer. Int Wound J. 2007;4:216-220.
9. Wu HG, Song SY, Kim YS et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer. A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer. 2009;15:3699-3708.
10. Shiraha H, Gupta K, Drabik K, Wells A. Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors. J Biol Chem. 2000;275:19343-19351. (Pubitemid 30422908)
11. Tran KT, Rusu SD, Satish L, Wells A. Aging-related attenuation of EGF receptor signaling is mediated in part by increased protein phosphatase activity. Exp Cell Res. 2003;289:359-367. (Pubitemid 37117422)
12. Benedetto AV. The environment and skin aging. Clin Dermatol. 1998;16:129-139. (Pubitemid 28303588)
13. Lee JY, Kim YK, Seo JY, et al. Loss of elastic fibers causes skin wrinkles in sun-damaged human skin. J Dermatol Sci. 2008;50:99-107.
14. Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura P et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6:331-346.
15. Mimura Y, Ihn H, Jinnin M, Asona Y, Yamane K, Tamaki K. Epidermal growth factor induces fibronectin expression in human dermal fibroblasts via protein kinase C delta signaling pathway. J Invest Dermatol. 2004;122:1390-1398. (Pubitemid 38757219)
16. Leyden JJ. Clinical features of aging skin. Br J Dermatol. 1990;122(Supp35):1-3.
17. Montagna W, Carlisle K. Structural changes in ageing skin. Br J Dermatol. 1990;122 (Suppl 35):61-70. (Pubitemid 20136110)
18. Wulf HC, Sandby-Moller J, Kobayasi T, Gniadecki R. Skin aging and natural photoprotection. Micron. 2004;35:185-191. (Pubitemid 38225244)
19. Uitto J, Fazio MJ, Olsen DR. Molecular mechanisms of cutaneous aging; age-associated connective tissue alterations in the dermis. J Am Acad Dermatol. 1989;1:614-622. (Pubitemid 19211185)
20. Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol. 2007;29:44-55. (Pubitemid 46220238)
21. Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol. 1990;94:624-629 (Pubitemid 20141280)
22. Mehta RC, Smith SR, Grove GL, et al. Reduction in facial photodamage by a topical growth factor product. J Drugs Dermatol. 2008;7:864-871.
23. DNAEGF Renewal tm Renewal Foaming Cleanser, Ingredients: Water, Laurylglucosides, Hydroxypropylsulfonate, Polyquaternium- 71, Guar Hydroxpropyl Trimonium Chloride, Polysorbate 20, Glycolic Acid, Cetrimonium Laureth-12 Succinate, PEG-7 Dimethicone, Arginine, Cetyl Hydroxyethicellulose, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Sodium Hydroxide, Caprylic/Capric Triglyceride, Citrus Paradisi (Grapefruit) Oil, Citrus Aurantium Dulcis (Orange) Fruit Extract, Citrus Reticulata (Tangerine) Oil.
24. DNAEGF Renewal tm DNA Defense SPF 30+, Active Ingredients: Ethylhexyl Methoxycinnamate 7.5%, Oxybenzone 4%, Zinc Oxide 3%, Phenylbenzamidazole Sulfonic Acid 2%.
25. BIOEFFECT EGF Serum Active Ingredients: Glycerine, Aqua, Sodium hyaluronate, Tromethamine, Alcohol (less than 0,9%), Calcium chloride, Sodium chloride, Hordeum vulgare seed extract, EGF (Transgenic barley sh-oligopeptide-1).